Chronic Treatment with Ivabradine Does Not Affect Cardiovascular Autonomic Control in Rats

Fernanda C Silva1, Franciny A Paiva1, Flávia C Müller-Ribeiro2

  • 1Laboratory of Cardiovascular Physiology, Department of Biological Sciences, Institute of Exact and Biological Sciences, Federal University of Ouro PretoOuro Preto, Brazil; Graduate Program in Biological Sciences - CBIOL/NUPEB, Federal University of Ouro PretoOuro Preto, Brazil.

Frontiers in Physiology
|August 11, 2016
PubMed

Insights

Ivabradine effectively lowers heart rate (HR) in rats by acting on hyperpolarization-activated cyclic nucleotide gated (HCN) channels. This study found that chronic ivabradine treatment reduces resting HR without altering autonomic control or renal sympathetic nerve activity (RSNA).

Area of Science:

  • Cardiovascular Physiology
  • Pharmacology
  • Autonomic Nervous System Research

Background:

  • A low resting heart rate (HR) is beneficial for cardiovascular diseases.
  • Ivabradine, a selective hyperpolarization-activated cyclic nucleotide gated (HCN) channel inhibitor, is a promising HR-lowering drug.
  • The effects of ivabradine on autonomic HR control are not well understood.

Purpose of the Study:

  • To assess the impact of chronic ivabradine treatment on cardiovascular autonomic control.
  • To investigate the effects of ivabradine on reflex and tonic autonomic control of HR.
  • To evaluate the influence of ivabradine on renal sympathetic nerve activity (RSNA).

Main Methods:

  • Male Wistar rats received daily intraperitoneal injections of vehicle (VEH) or ivabradine (IVA) for 7-8 days.
  • Arterial blood pressure (AP) and HR were recorded in freely moving rats, with cardiovascular variability parameters analyzed.
  • Baroreflex, chemoreflex, Bezold-Jarish reflex sensitivities, and autonomic blockade were assessed; AP, HR, and RSNA were recorded in anesthetized rats.

Main Results:

  • Ivabradine-treated rats exhibited significantly lower resting and intrinsic HR compared to controls.
  • Chronic ivabradine treatment did not alter normalized HR spectral parameters (LF (nu), HF (nu)).
  • No significant changes were observed in cardiovascular reflex sensitivities, tonic autonomic control of HR, RSNA, or mean arterial pressure.

Conclusions:

  • In healthy rats, long-term ivabradine treatment directly reduces HR.
  • Ivabradine does not affect RSNA modulation or the reflex and tonic autonomic control of the heart.
  • Ivabradine demonstrates potential as an HR-lowering agent with specific effects on HCN channels, independent of broad autonomic modulation.

Related Concept Videos

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
2.5K
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
2.2K
Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
577
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
2.8K
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
4.0K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.4K